Hydroxychloroquine versus methotrexate for frontal fibrosing alopecia
Treatments studied
Part of Skin clinical trials.
This study compares two medications, hydroxychloroquine and methotrexate, to see which works better for treating frontal fibrosing alopecia, a condition that causes hair loss at the front of the scalp. You'll be assigned to one of the two treatments, and your progress will be followed during routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with frontal fibrosing alopecia.
- You are willing to take one of the two study medications.
- You can understand Dutch.
- You do not have any known allergies or medical conditions that prevent you from taking hydroxychloroquine or methotrexate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cream called delgocitinib for a type of hair loss that affects the front of the scalp and eyebrows. The cream may help reduce redness and scaling and potentially slow or stop the hair loss.
This study tests whether laser therapy can help treat small bumps (papules) that appear on the face in people with frontal fibrosing alopecia, a type of hair loss. If you have these bumps and are generally healthy, you may be able to join.
This study compares two medicines, cyclosporine and methotrexate, to see which works better for children with alopecia areata (a condition causing hair loss). It aims to help doctors choose the best treatment for each child.
This study tests whether a methotrexate lotion or minoxidil lotion is better at regrowing hair in people with patchy hair loss on the scalp. You will use one of the treatments for a period of time, and the doctors will check your progress.
This study compares two existing medicines — tofacitinib and methotrexate — to see which one is better at treating severe alopecia areata, a condition that causes patchy or total hair loss. If you have severe hair loss, this trial might help you find an effective treatment.
This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.
Hear when a new Frontal Fibrosing Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.